StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where MRK sits in our scored universe today on a single observational measurement. P85 means MRK ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $120.55 | $122.41 | +1.54% | 14.8M |
| 05-26 | $122.90 | $119.72 | -2.59% | 10.0M |
| 05-27 | $119.82 | $120.24 | +0.35% | 7.2M |
| 05-28 | $120.26 | $119.89 | -0.31% | 9.3M |
| 05-29 | $119.65 | $118.72 | -0.78% | 16.6M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $16.29B | $65.01B | $48.61B | $31.34B |
Operating Income | $-3.53B | $21.07B | $17.65B | $10.90B |
Net Income | $-4.24B | $18.25B | $15.29B | $9.51B |
EPS (Diluted) | $-1.72 | $7.28 | $6.08 | $3.77 |
Total Assets | $128.69B | $136.87B | $129.55B | $117.52B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $5.33B | $14.56B | $18.17B | $8.01B |
Free Cash Flow OCF − CapEx | $2.93B | $12.36B | $10.54B | $3.70B |
Shares Outstanding | 2.47B | 2.51B | 2.51B | 2.52B |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).